PGL is on a steady downtrend to $1.40-$1.50 as Nexavar continues...

PGL is on a steady downtrend to $1.40-$1.50 as Nexavar continues to gain momentum and market share. Nexavar will soon be approved for resectable liver which was Progen's intended market. To put it mildly their business plan is in serious trouble. Buy now and expect to be burned as it goes lower. There is no shame in being scooped by a blockbuster drug like Nexavar but it happens and they need to face up to reality. The lung cancer failure shuts the door on their only escape route. Goodbye Progen it was nice knowing you.